Redhill Biopharma
RDHL
S$1.91
Share price
-9.20%
Change (1 day)
-85.55%
Change (1 year)
Categories
Redhill Biopharma (RDHL) - Total debt
Total debt on the balance sheet as of December 2024 : S$0.45 Million
According to Redhill Biopharma's latest financial reports the company's total debt is S$0.45 Million. A company’s total debt is the sum of all current and non-current debts.
Redhill Biopharma - Total debt on balance sheet (from 2018 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | S$1.54 M | -99.06% |
| 2022-12-31 | S$0.16 B | 38.55% |
| 2021-12-31 | S$0.11 B | 3.26% |
| 2020-12-31 | S$0.11 B | 2135.28% |
| 2019-12-31 | S$5.14 M | |
| 2018-12-31 | N/A |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | S$29.31 B | 6,396,107.87% | 🇫🇷 France |
 Merck MRK | S$44.86 B | 9,787,540.45% | 🇺🇸 USA |
 GlaxoSmithKline GSK | S$30.66 B | 6,689,731.46% | 🇬🇧 UK |
 Taro Pharmaceutical TARO | S$2.51 M | 447.75% | 🇮🇱 Israel |
 Teva Pharmaceutical Industries TEVA | S$21.80 B | 4,758,046.07% | 🇮🇱 Israel |